Nonsteroidal antiinflammatory drug desensitization using flurbiprofen (Ansaid)
Nonsteroidal antiinflammatory drug (NSAID) and aspirin reactions remain commonplace. Specific recommendations and standardized approaches to the use of NSAIDs in patients with known hypersensitivity to these agents are evolving. Cross reactivity and sensitization are frequent within this group of agents. The advent of newer synthetic nonsteroidal antiinflammatory drugs may offer a means of lowering reaction rates. Flurbiprofen (Ansaid) is a new NSAID for the treatment of rheumatoid arthritis and osteoarthritis. We report successful flurbiprofen desensitization with incremental oral challenge in a patient using this agent.
Douglas
D M
DM
Department of Internal Medicine, Madigan Army Medical Center, Tacoma, Washington.
Ward
L
L
Brown
J S
JS
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000276:immunology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000009:adverse effects* / Q000276:immunology; D003429:Cross Reactions; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000209:etiology; D004361:Drug Tolerance; D005260:Female; D005480:Flurbiprofen / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005480:Flurbiprofen; D001241:Aspirin